116
Participants
Start Date
September 16, 2008
Primary Completion Date
March 3, 2014
Study Completion Date
March 3, 2014
Darbepoetin Alfa
Administered by subcutaneous or intravenous injection
Placebo
Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
Research Site, Jūrmala
Research Site, Edegem
Research Site, Leuven
Research Site, Ghent
Research Site, New York
Research Site, The Bronx
Research Site, Valhalla
Research Site, New Hyde Park
Research Site, Buffalo
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Aguascalientes
Research Site, Baltimore
Research Site, Charlottesville
Research Site, Richmond
Research Site, Norfolk
Research Site, Charlotte
Research Site, Chihuahua City
Research Site, Gainesville
Research Site, Orlando
Research Site, Miami
Research Site, Birmingham
Research Site, Louisville
Research Site, Columbus
Research Site, Cleveland
Research Site, Cleveland
Research Site, Akron
Research Site, Cincinnati
Research Site, Iowa City
Research Site, Chicago
Research Site, Kansas City
Research Site, New Orleans
Research Site, Puebla City
Research Site, Dallas
Research Site, Houston
Research Site, San Antonio
Research Site, Boise
Research Site, Albuquerque
Research Site, Los Angeles
Research Site, Los Angeles
Research Site, San Diego
Research Site, San Francisco
Research Site, Portland
Research Site, Portland
Research Site, Seattle
Research Site, Moscow
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Krasnodar
Research Site, Samara
Research Site, Orenburg
Research Site, Stanford
Research Site, Boston
Research Site, Livingston
Research Site, New Brunswick
Research Site, Vilnius
Research Site, Mexico City
Research Site, Gdansk
Research Site, Lodz
Research Site, Szczecin
Research Site, San Juan
Research Site, Banská Bystrica
Research Site, Bratislava
Research Site, Košice
Research Site, Birmingham
Research Site, Leeds
Research Site, London
Lead Sponsor
Amgen
INDUSTRY